Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A user recommends using a microscope to assess hair density and track hair loss progress, finding it useful for evaluating treatment effectiveness, particularly with dutasteride and minoxidil. They advise against obsessing over hair loss and emphasize focusing on other meaningful life aspects.

The conversation is about the preference for using a derma stamp over a derma roller for hair loss treatment, with users discussing its efficiency, needle material, replacement frequency, and personal experiences. Specific treatments mentioned include microneedling with a derma stamp.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.

The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

A user's successful hair transplant, with some people questioning the donor area regrowth, and others speculating that hair fibre may have been used to help fill in areas.

The conversation discusses hair regrowth after 7 months of treatment, with the recent addition of tretinoin 0.05%. The treatment routine remained the same as before, except for this new addition.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

Considering adding Low Level Laser Therapy (LLLT) to a hair loss prevention regimen; discussing the effectiveness of LLLT, and evaluating double-blind random-controlled trials that have been conducted on laser combs.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

A 36-year-old is experiencing underwhelming results from derma stamping for hair thinning, using needle lengths of 0.5mm to 0.75mm. They are considering increasing needle length, taking a break, or pairing the treatment with rosemary oil.

L'Oreal Serioxyl and Garnier Fructus Stemoxydine are compared for effectiveness in hair loss treatment. The user considers switching from Serioxyl to the cheaper Garnier Fructus but is unsure about its effectiveness and stemoxydine percentage.

Stemoxydine is a hair loss treatment discussed in a forum. Its effectiveness is questioned by users.

Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.

Hair regrowth treatments, including stem cell injections, are discussed, with skepticism about their effectiveness compared to Minoxidil and finasteride. Derma stamping is mentioned as effective when used with Minoxidil, finasteride, and dutasteride.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

A user who shared progress pictures of their scalp using a microscope camera, demonstrating the difference between healthy and miniaturized hair. Various explanations for the cause of this were discussed, such as DHT build-up in scalp sebum causing an autoimmune response leading to inflammation and eventual hair loss, with some suggesting a do-it-yourself treatment involving adding ascorbic acid powder to shampoo.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.